-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post ADCs, mAbs, CAR Ts:...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoRoivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBrainChild hauls in $116M to make cell therapies for childhood brain cancers
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoBristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoModerna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months ago1,5-Pentanediamine from CRKP-colonized patients weakens CD19 CAR-T cells in vitro
A bacterial metabolite that circulates in the blood of patients colonized with carbapenem-resistant Klebsiella pneumoniae appears to sabotage one of modern medicine’s most powerful cancer therapies,...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoAltered lncRNA profiles in breast cancer NK cells impair immune function
In a discovery that could reshape how scientists think about cancer immunosurveillance, researchers have uncovered striking abnormalities in the long non-coding RNA landscape of natural killer...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoNewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy
The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s proprietary cell engineering and rAAV manufacturing...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoGilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSTAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
The latest pharma news from the Pharmalot campus brought to you by the Pharmalittle newsletter
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
